Fate Therapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.3M | 1.4M | 1.7M | 1.9M | 1.6M | 1.9M | 3.1M | 6.8M |
| Cost of Goods Sold | 2.9M | 0 | 25.8M | 3.8M | 29.1M | 17.1M | 34.6M | 4.7M |
| Gross Profit | -1.6M | 1.4M | -24.1M | -1.9M | -27.5M | -15.3M | -31.6M | 2.1M |
| R&D Expenses | 21.8M | 25.4M | 25.8M | 27.4M | 29.1M | 33.6M | 34.6M | 34.6M |
| Operating Expenses | 31.4M | 36.1M | 10.6M | 35.1M | 13.8M | 46.5M | 20.8M | 47.1M |
| Operating Income | -33.0M | -34.7M | -34.7M | -37.0M | -41.3M | -61.7M | -52.4M | -45.1M |
| Other Income / Gains | 1.8M | 2.3M | 2.5M | 2.9M | 3.7M | 9.6M | 4.7M | 6.7M |
| Net Income | -31.2M | -32.4M | -32.3M | -34.1M | -37.6M | -52.2M | -47.7M | -38.4M |
| EPS (Diluted) | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 | -0.33 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | -1.246 | 1.00 | -13.841 | -1.004 | -16.886 | -8.215 | -10.272 | 0.303 |
| General And Administrative Expenses | 9.6M | 10.7M | 10.6M | 11.4M | 13.8M | 15.3M | 20.8M | 17.3M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 16.5M | 0 | 0 |
| Selling General And Administrative Expenses | 9.6M | 10.7M | 10.6M | 11.4M | 13.8M | 31.7M | 20.8M | 17.3M |
| Other Expenses | 0 | 0 | -25.8M | -3.8M | -29.1M | -18.9M | -34.6M | -4.7M |
| Cost And Expenses | 34.3M | 36.1M | 36.5M | 38.9M | 42.9M | 63.6M | 55.5M | 51.9M |
| Interest Income | 1.9M | 2.2M | 2.6M | 2.9M | 3.3M | 3.9M | 4.4M | 4.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation And Amortization | 2.9M | 3.1M | 3.2M | 3.3M | 3.3M | 4.8M | 4.6M | 4.7M |
| Ebitda | -28.3M | -29.3M | -29.0M | -30.8M | -34.3M | -42.2M | -43.1M | -33.7M |
| Ebitdaratio | -21.782 | -21.411 | -16.67 | -16.147 | -21.048 | -22.687 | -14.011 | -4.977 |
| Operating Income Ratio | -25.404 | -25.362 | -19.951 | -19.385 | -25.341 | -33.198 | -17.039 | -6.657 |
| Income Before Tax | -31.2M | -32.4M | -32.3M | -34.1M | -37.6M | -52.2M | -47.7M | -38.4M |
| Income Before Tax Ratio | -24.028 | -23.648 | -18.524 | -17.866 | -23.095 | -28.039 | -15.51 | -5.674 |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income Ratio | -24.028 | -23.648 | -18.524 | -17.866 | -23.095 | -28.039 | -15.51 | -5.674 |
| Epsdiluted | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.40 | -0.33 |
| Weighted Average Shs Out | 120.0M | 118.8M | 119.0M | 118.5M | 118.4M | 117.8M | 117.8M | 117.5M |
| Weighted Average Shs Out Dil | 120.0M | 118.8M | 119.0M | 118.5M | 118.4M | 117.8M | 117.8M | 117.5M |